Neonatal Lactose Intolerance: New Expert Consensus on Diagnosis and Care
Published online on March 27, 2026, in Pediatric Discovery (DOI: 10.1002/pdi3.70044), a new expert consensus provides 10 practical recommendations for managing neonatal lactose intolerance, particularly in premature infants.
- Newborn lactose intolerance stems primarily from digestive immaturity or intestinal injury rather than rare inherited disorders.
- The consensus recommends continuing breastfeeding alongside lactase supplementation for symptomatic breastfed infants.
- Routine or preventive use of lactose-free formula is discouraged as a first-line feeding choice.
Clinical Background and Diagnostic Challenges in Newborns
Lactose serves as a major carbohydrate in human milk. Breaking it down requires lactase, an intestinal enzyme that often appears in insufficient quantities in babies born prematurely. In newborns, lactose intolerance typically links back to digestive immaturity or intestinal injury. Its external signs—including crying, regurgitation, abdominal swelling, and loose stools—frequently mimic symptoms of infections, cow’s milk protein allergy, and more dangerous intestinal diseases.
Diagnostic hurdles compound these clinical challenges. Tests designed for older children remain unreliable or impractical in newborns. Unnecessary dietary changes risk compromising crucial infant nutrition. Because accurate diagnosis and feeding choices stay difficult, systematic investigation remains necessary to establish consistent clinical approaches.
Development and Recommendations of the 2025 Expert Consensus
Coordinated through the National Clinical Research Center for Child Health and Disorders in Chongqing, with contributors from the Children’s Hospital of Chongqing Medical University and other Chinese institutions, a multidisciplinary working group developed the guidance. Yuan Shi served as corresponding author for the overall design, translating existing evidence and clinical experience into actionable advice. The working group reviewed 61 publications, including randomized controlled trials, observational studies, systematic reviews, and earlier guidance. The authors assessed evidence using the GRADE approach and applied a modified Delphi process where evidence was limited.
The resulting diagnostic pathway begins with evaluating symptoms and stool changes, including unusually acidic-smelling stools. For symptomatic newborns, fecal reducing sugar tests or urinary galactose assays support initial screening, though neither test alone establishes a definitive diagnosis. Clinicians must exclude conditions like necrotizing enterocolitis and cow’s milk protein allergy before considering a supervised diagnostic elimination test to assess whether symptoms improve with lactase supplementation or reduced lactose intake.
For breastfed infants with lactose intolerance, the consensus offers a strong recommendation to continue breastfeeding while adding lactase. Formula-fed infants may receive lactase or reduced-lactose formula. Lactose-free formula is not recommended for routine first-line or preventive feeding. Treatment generally runs for at least two weeks, with the duration adjusted according to clinical recovery. Probiotics producing β-galactosidase are described as possible adjuncts, although neonatal evidence remains limited and safety concerns require caution in very premature infants. The guidance favors lactase preparations with demonstrated safety and efficacy.
Clinicians Should Prioritize Symptoms over Lactose Avoidance
The authors emphasize that feeding decisions should respond directly to a baby’s symptoms and clinical condition rather than an assumption that lactose must always be avoided. The guidance is designed to assist medical professionals in separating lactose intolerance from alternative sources of feeding trouble while maintaining the developmental benefits of human milk.
Evidence remains uneven, particularly for extremely premature infants and probiotic treatments. The consensus offers a practical starting point for consistent care rather than a substitute for individualized assessment or stronger clinical trials. Neonatal intensive care teams and pediatric clinicians gain a step-by-step framework for deciding when to test, intervene, or reconsider a diagnosis. The recommendations apply to newborns and preterm infants below 44 weeks of corrected gestational age, excluding severely ill babies and those with rare congenital lactase deficiency. The investigators emphasize the necessity of expanded, randomized controlled studies to better define optimal intervention schedules, extended health trajectories, and probiotic safety profiles among extremely premature babies.